Taxanes: impact on breast cancer therapy.

Lohith S. Bachegowda, Della F. Makower, Joseph A. Sparano

Research output: Contribution to journalArticle

Abstract

Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)512-521
Number of pages10
JournalAnti-Cancer Drugs
Volume25
Issue number5
StatePublished - 2014
Externally publishedYes

Fingerprint

Taxoids
Breast Neoplasms
docetaxel
Appointments and Schedules
Cytotoxins
Biological Factors
Therapeutics
Paclitaxel

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Taxanes : impact on breast cancer therapy. / Bachegowda, Lohith S.; Makower, Della F.; Sparano, Joseph A.

In: Anti-Cancer Drugs, Vol. 25, No. 5, 2014, p. 512-521.

Research output: Contribution to journalArticle

@article{bacf5f6cfc234453857bb8aa9d8c1321,
title = "Taxanes: impact on breast cancer therapy.",
abstract = "Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer.",
author = "Bachegowda, {Lohith S.} and Makower, {Della F.} and Sparano, {Joseph A.}",
year = "2014",
language = "English (US)",
volume = "25",
pages = "512--521",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Taxanes

T2 - impact on breast cancer therapy.

AU - Bachegowda, Lohith S.

AU - Makower, Della F.

AU - Sparano, Joseph A.

PY - 2014

Y1 - 2014

N2 - Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer.

AB - Taxanes play an important role in the management of early-stage and advanced-stage breast cancer. Initial studies sought to determine whether there was antitumor activity in patients with metastatic disease, and identify the optimal agent, dose, and schedule. Subsequent studies established a role for both paclitaxel and docetaxel as adjuvant therapy, determined whether they should be administered concurrently or sequentially with other cytotoxic agents, and also determined the optimal agent, dose, and schedule. Taxanes have also been combined with biologic agents, including anti-HER2-directed therapy and antiangiogenic therapy. The aim of this article is to provide a review of pivotal trials evaluating taxane therapy that have informed the current approach for the use of taxanes in early-stage and advanced-stage breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84908365490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908365490&partnerID=8YFLogxK

M3 - Article

C2 - 24552749

VL - 25

SP - 512

EP - 521

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -